

# Naoki Kawagishi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3809871/publications.pdf>

Version: 2024-02-01

37  
papers

639  
citations

471061

17  
h-index

610482

24  
g-index

38  
all docs

38  
docs citations

38  
times ranked

909  
citing authors

#	ARTICLE	IF	CITATIONS
1	L-carnitine suppresses loss of skeletal muscle mass in patients with liver cirrhosis. <i>Hepatology Communications</i> , 2018, 2, 910-922.	2.0	67
2	Early response and safety of lenvatinib for patients with advanced hepatocellular carcinoma in a real-world setting. <i>JGH Open</i> , 2020, 4, 54-60.	0.7	36
3	Comparing the risk of hepatitis B virus reactivation between direct-acting antiviral therapies and interferon-based therapies for hepatitis C. <i>Journal of Viral Hepatitis</i> , 2017, 24, 1098-1106.	1.0	35
4	Lenvatinib in patients with unresectable hepatocellular carcinoma who do not meet the REFLECT trial eligibility criteria. <i>Hepatology Research</i> , 2020, 50, 966-977.	1.8	35
5	Retreatment with sofosbuvir, ledipasvir, and add-on ribavirin for patients who failed daclatasvir and asunaprevir combination therapy. <i>Journal of Gastroenterology</i> , 2017, 52, 1122-1129.	2.3	32
6	Entecavir treatment of hepatitis B virus-infected patients with severe renal impairment and those on hemodialysis. <i>Hepatology Research</i> , 2019, 49, 1294-1304.	1.8	32
7	Liver steatosis and dyslipidemia after HCV eradication by direct acting antiviral agents are synergistic risks of atherosclerosis. <i>PLoS ONE</i> , 2018, 13, e0209615.	1.1	29
8	Tenofovir disoproxil fumarate modulates lipid metabolism via hepatic CD36/PPAR-alpha activation in hepatitis B virus infection. <i>Journal of Gastroenterology</i> , 2021, 56, 168-180.	2.3	29
9	Analysis of the optimal psoas muscle mass index cutoff values, as measured by computed tomography, for the diagnosis of loss of skeletal muscle mass in Japanese people. <i>Hepatology Research</i> , 2020, 50, 715-725.	1.8	28
10	Prevalence, clinical course, and predictive factors of immune checkpoint inhibitor monotherapy-associated hepatitis in Japan. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 1782-1788.	1.4	22
11	Hepatitis B virus reactivation during hepatitis C direct-acting antiviral therapy in patients with previous HBV infection. <i>Journal of Hepatology</i> , 2017, 67, 1106-1108.	1.8	21
12	Safety and efficacy of glecaprevir and pibrentasvir in Japanese hemodialysis patients with genotype 2 hepatitis C virus infection. <i>Journal of Gastroenterology</i> , 2019, 54, 641-649.	2.3	21
13	Tri-antennary tri-sialylated mono-fucosylated glycan of alpha-1 antitrypsin as a non-invasive biomarker for non-alcoholic steatohepatitis: a novel glycobiomarker for non-alcoholic steatohepatitis. <i>Scientific Reports</i> , 2020, 10, 321.	1.6	21
14	High serum angiopoietin-2 level predicts non-regression of liver stiffness measurement-based liver fibrosis stage after direct-acting antiviral therapy for hepatitis C. <i>Hepatology Research</i> , 2020, 50, 671-681.	1.8	20
15	Early response and safety of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma in patients who do not meet IMbrave150 eligibility criteria. <i>Hepatology Research</i> , 2021, 51, 979-989.	1.8	20
16	Safety and efficacy of elbasvir and grazoprevir in Japanese hemodialysis patients with genotype 1b hepatitis C virus infection. <i>Journal of Gastroenterology</i> , 2019, 54, 78-86.	2.3	19
17	Assessing the risk of hepatocellular carcinoma by combining liver stiffness and the controlled attenuation parameter. <i>Hepatology Research</i> , 2019, 49, 1207-1217.	1.8	19
18	Effect of switching from tenofovir disoproxil fumarate to tenofovir alafenamide on lipid profiles in patients with hepatitis B. <i>PLoS ONE</i> , 2022, 17, e0261760.	1.1	17

#	ARTICLE	IF	CITATIONS
19	Safety and efficacy of sofosbuvir and ribavirin for genotype 2 hepatitis C Japanese patients with renal dysfunction. <i>Hepatology Research</i> , 2018, 48, 529-538.	1.8	15
20	Baseline angiopoietin-2 and FGF19 levels predict treatment response in patients receiving multikinase inhibitors for hepatocellular carcinoma. <i>JGH Open</i> , 2020, 4, 880-888.	0.7	13
21	A Phase I Study of Combination Therapy with Sorafenib and 5-Fluorouracil in Patients with Advanced Hepatocellular Carcinoma. <i>Drugs in R and D</i> , 2017, 17, 381-388.	1.1	12
22	Time-dependent changes in the seroprevalence of COVID-19 in asymptomatic liver disease outpatients in an area in Japan undergoing a second wave of COVID-19. <i>Hepatology Research</i> , 2020, 50, 1196-1200.	1.8	11
23	Characteristics and Lenvatinib Treatment Response of Unresectable Hepatocellular Carcinoma with Iso-High Intensity in the Hepatobiliary Phase of EOB-MRI. <i>Cancers</i> , 2021, 13, 3633.	1.7	10
24	Effects of resistance-associated variants in genotype 2 hepatitis C virus on viral replication and susceptibility to anti-hepatitis C virus drugs. <i>Hepatology Research</i> , 2019, 49, 1275-1285.	1.8	8
25	Computed tomography, not bioelectrical impedance analysis, is the proper method for evaluating changes in skeletal muscle mass in liver disease. <i>JCSM Rapid Communications</i> , 2020, 3, 103-114.	0.6	8
26	Baseline elevated serum angiopoietin-2 predicts long-term non-regression of liver fibrosis after direct-acting antiviral therapy for hepatitis C. <i>Scientific Reports</i> , 2021, 11, 9207.	1.6	8
27	Frequency and Characteristics of Overestimated Renal Function in Japanese Patients with Chronic Liver Disease and Its Relation to Sarcopenia. <i>Nutrients</i> , 2021, 13, 2415.	1.7	8
28	Changes in the estimated renal function after hepatitis C virus eradication with direct-acting antiviral agents: Impact of changes in skeletal muscle mass. <i>Journal of Viral Hepatitis</i> , 2021, 28, 755-763.	1.0	6
29	Possible correlation between increased serum free carnitine levels and increased skeletal muscle mass following HCV eradication by direct acting antivirals. <i>Scientific Reports</i> , 2021, 11, 16616.	1.6	6
30	Changes in Serum Growth Factors during Lenvatinib Predict the Post Progressive Survival in Patients with Unresectable Hepatocellular Carcinoma. <i>Cancers</i> , 2022, 14, 232.	1.7	6
31	The Successful Retreatment with Glecaprevir and Pibrentasvir of Genotype 1 or 2 HCV-infected Hemodialysis Patients who Failed to Respond to NS5A and Protease Inhibitor Treatment. <i>Internal Medicine</i> , 2019, 58, 943-947.	0.3	5
32	Durable response without recurrence to Tolvaptan improves long-term survival. <i>Journal of Gastroenterology</i> , 2020, 55, 1150-1161.	2.3	4
33	Glecaprevir and Pibrentasvir for Japanese Patients with Human Immunodeficiency Virus and Genotype 3 Hepatitis C Virus Coinfection: A Report of Three Cases. <i>Internal Medicine</i> , 2019, 58, 797-802.	0.3	4
34	Effects of nucleos(t)ide analogs on hepatitis B surface antigen reduction with interferon- $\lambda$ 3 induction in chronic hepatitis B patients. <i>Hepatology Research</i> , 2022, 52, 586-596.	1.8	4
35	Overestimated Renal Function in Patients with Liver Cirrhosis Predicts Poor Prognosis. <i>Hepatology Research</i> , 2022, , .	1.8	4
36	Baseline serum angiopoietin-2 and VEGF levels predict the deterioration of the liver functional reserve during lenvatinib treatment for hepatocellular carcinoma. <i>PLoS ONE</i> , 2021, 16, e0247728.	1.1	3

#	ARTICLE	IF	CITATIONS
37	Add-on effects of fluvastatin in simeprevir/pegylated-interferon/ribavirin combination therapy for patients with genotype 1 hepatitis C virus infection: A randomized controlled study. <i>Hepatology Research</i> , 2018, 48, E146-E154.	1.8	1